Sarcoma News

New results from the prospective, longitudinal Life Span Study of Japanese atomic bomb survivors from Hiroshima and Nagasaki show that low levels of exposure to ionizing radiation may result in soft-tissue sarcoma, and 1 Gy doses nearly doubled the survivors’ sarcoma risk.

The FDA today approved the first generic version of the cancer drug doxorubicin hydrochloride liposome injection, used to treat ovarian cancer, AIDS-related Kaposi’s sarcoma and multiple myeloma.

A radiation “cone-down” boost was associated with treatment volume reductions of more than 50% in a cohort of patients with pediatric rhabdomyosarcoma.

Sorafenib appears to be a promising treatment for patients with leiomyosarcoma, according to results from a phase 2 study.

Combination analysis with [18F] fluorodeoxyglucose PET/CT was 20% more accurate than contrast-enhanced CT alone in detecting bone or soft tissue sarcoma, according to study results.

Patients with localized Ewing’s sarcoma who underwent chemotherapy administered every 2 weeks experienced superior outcomes compared with those who underwent chemotherapy every 3 weeks, according to study results.

Long-term survivorship was increased in patients with post-radiation sarcoma if they had bone sarcoma or underwent surgery combined with chemotherapy, according to researchers at Rizzoli Orthopaedic Institute in Bologna.

Denosumab increases bone formation and decreases the number of giant cells by 90% in patients with giant-cell tumor of the bone. Additionally, the drug may be useful in the treatment of patients with giant-cell tumor of the bone (GCTB) who surgeons may otherwise choose to recommend for joint replacement procedures, according to researchers from California.

The FDA announced that Samantha Lynn Inc. has voluntarily recalled 500 lots of Reumofan Plus tablets because of undeclared drug ingredients.

The use of liquefied phenol during intralesional curettage of low-grade malignant bone tumors is safe when washed out with ethanol, according to study results. Intralesional curettage is a surgical procedure typically performed on patients with low-grade bone tumors. The technique, however, carries the risk of tumor cell recurrence.